The medication is applied across therapeutic domains involving diseases caused by parasitic worms, known as helminths. It serves as a versatile treatment across several domains, generally used in situations involving symptoms related to systemic imbalance and localized discomfort caused by parasitic worms. The treatment is commonly used to help with conditions characterized by periods of heightened symptoms resulting from these infections.

Therapeutic Use Categories

The medication is commonly used in conditions that involve the invasion of deep body tissues and vital organs by parasitic worm larvae (cestodes), such as Neurocysticercosis and Cystic Hydatid Disease, and for common parasitic infestations found in the digestive tract, including roundworms, hookworms, and pinworms. This range of activity is relevant in situations where patients experience both complex tissue infections and common gut burdens. It is commonly used to help with supportive relief during difficult episodes by easing the overall symptom load, which may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Parasitic Symptoms
Primary Focus	Systemic clearance of larval cestodes and intestinal nematodes.
Symptom Management	Assists in easing neurological strain and chronic GI distress.
Use Context	Applied in public health scenarios and for complex tissue infections.

Regulatory References

1. NIH MedlinePlus Drug Information on Albendazole

Eligibility and Contraindications for Nemozol (Albendazole)

The official eligibility criteria for Nemozol are strictly defined by regulatory documents based on patient profile and existing clinical states. The medicine is not suitable for all individuals.

Classification	Populations and Conditions
Absolutely Contraindicated	Pregnant women or women suspected of being pregnant. Hypersensitivity (allergy) to albendazole, other benzimidazole compounds, or any tablet component.
Use Restricted / Not Recommended	Women of childbearing potential must use effective contraception during and for a specified time (e.g., one month) after treatment. Children under 2 years of age are generally not recommended for treatment due to limited experience.
Requires Close Monitoring	Patients with pre-existing liver disease (hepatic impairment) or elevated liver enzymes. Patients with a history of bone marrow suppression or those at risk of low blood counts (leukopenia, pancytopenia).

All patients must undergo regular monitoring of liver function tests and blood cell counts throughout the course of treatment. The use of the medicine must be immediately discontinued if clinically significant decreases in blood counts or significant increases in liver enzymes are observed. In cases of neurocysticercosis, an eye examination for retinal lesions may be required before starting therapy.

Interactions with other medicines and products

The interaction profile for Albendazole (Немозол) is governed by pharmacokinetic interactions that alter the systemic concentration of its active metabolite, Albendazole sulfoxide. These patterns are documented in government regulatory sources and fall into categories based on whether they increase or decrease drug exposure.

Pharmacokinetic Increase in Exposure

Co-administration with specific medicines is documented to increase the concentration of Albendazole sulfoxide. Dexamethasone co-administration is associated with an approximately 56% increase in trough concentrations. Praziquantel can increase the active metabolite’s plasma exposure by approximately 50%, while Cimetidine has been shown to increase concentrations in tissue fluid by up to 2-fold.

Pharmacokinetic Decrease in Exposure

Other substances may lead to a decrease in systemic exposure. Anticonvulsant medicines, including Phenytoin, Carbamazepine, and Phenobarbital, are noted to reduce the active metabolite’s plasma concentrations due to enzyme induction. The protease inhibitor Ritonavir is also documented as potentially decreasing exposure levels.

Interaction Type	Interacting Substance	Official Effect
Food/Timing	High-Fat Meal	Systemic absorption increases significantly (up to 9.4-fold)
Substance	Grapefruit Juice	Increases plasma levels of the active metabolite
Population Note	Hepatic Impairment	Increased risk of exposure-related complications

No medicinal product combinations are formally classified as contraindicated due to interaction risk. The documented interactions establish constraints that require regulatory caution based on the magnitude of the resulting change in exposure.

The biological effect of Nemozol, whose active ingredient is Albendazole, is characterized by a specific interference with fundamental parasitic processes.

Molecular Target: Destabilizing the Parasite's Cellular Skeleton

The drug acts primarily on the beta-tubulin subunit within the parasite's cells. The active metabolite, Albendazole sulfoxide, binds tightly to this protein, acting as a microtubule-destabilizing agent by preventing the assembly of new microtubules . This targeted action dismantles the core cellular infrastructure, especially in the parasite's intestinal and absorptive cells, which leads to the physiological consequence of structural degradation.

Mechanistic Cascade: Inhibiting Nutrient Uptake and Inducing Energy Failure

The collapse of the cellular structure critically impairs the parasite's ability to absorb glucose from the host environment. This interference with the parasite's glucose utilization pathway rapidly depletes its stored energy (glycogen), leading to a profound, irreversible ATP deficit. The resulting functional paralysis and metabolic failure lead to death of the helminth and its subsequent expulsion.

️ Biological Constraint: Mechanism Dependence on Parasite Activity

The drug's action is most effective against metabolically active, dividing parasitic cells that are highly dependent on continuous microtubule turnover and nutrient uptake. Forms of the parasite that are quiescent, such as fully mature or calcified cysts in certain deep-tissue infections, are less susceptible to the microtubule-binding mechanism, representing a natural constraint on the drug's physiological reach.

How to Use Nemozol (Albendazole): Administration Guidelines

Nemozol (Albendazole) is administered exclusively via the oral route, available as a tablet (which may be chewed or crushed) or as an oral suspension. The administration rules for this anthelmintic agent vary based on the type of parasitic infection being treated.

---

Core Administration Requirements

Feature	Instruction	Rationale
Route & Form	Oral Tablet or Suspension. Tablets may be crushed/chewed.	Facilitates swallowing, especially for children.
Timing with Food	Must be taken with a fatty meal.	Significantly enhances the systemic absorption of the active compound.

---

Standard Dosing and Use Patterns

Treatment falls into two primary categories defined by duration and frequency:

• Long-Term Systemic Infections (e.g., Neurocysticercosis, Hydatid Disease): The standard dose for adults ge 60 kg is 400 mg taken twice daily (BID). Dosing for patients < 60 kg is calculated based on weight (15 mg/ kg/ day in two divided doses), with a maximum daily dose of 800 mg.

  • Cyclic Use: Treatment for Hydatid Disease involves 28-day treatment cycles, separated by a 14-day drug-free interval.

• Short-Term Intestinal Infections (e.g., Roundworm, Hookworm): A single 400 mg dose is commonly prescribed for many common parasitic worms, while other infections may require 400 mg once daily for 3 consecutive days.

---

Population-Specific Instructions

For pediatric patients, the oral suspension formulation is recommended, and dosing for systemic infections follows the weight-based 15 mg/ kg/ day rule. No specific dose adjustment is generally required for patients with renal impairment.

Research Evidence / Overview of Studies

This section summarizes the research that has evaluated patient outcomes with Немозол (Albendazole), a widely studied anti-helminthic agent.

---

Efficacy against Soil-Transmitted Helminths (STHs)

Research has consistently explored the drug's use for treating STH infections, including hookworm, Ascaris lumbricoides, and Trichuris trichiura.

• Hookworm and A. lumbricoides: Clinical studies and systematic reviews have demonstrated high rates of success, often reporting egg reduction rates (ERRs) above 90–95% following a single dose regimen for these specific infections.
• T. trichiura (Whipworm): The observed efficacy against whipworm is generally lower and more variable, with reported cure rates and ERRs often falling below the thresholds established by the World Health Organization (WHO) for effective treatment.

---

Research in Complex Infections and Regimens

Studies have also examined the drug's role in treating more complex parasitic diseases, such as neurocysticercosis and cystic hydatid disease.

• Combination Therapies: For certain infections, such as Loa loa or specific STH cases, studies have investigated co-administration with other anti-parasitic agents (e.g., ivermectin or praziquantel) and have noted a variability in findings or different outcomes compared to monotherapy.
• Dosing and Duration: Research indicates that the outcomes, particularly for less susceptible parasites, can be influenced by the treatment duration, with multi-day regimens sometimes showing improved results in certain populations compared to a single dose.

Ongoing global surveillance monitors the effectiveness of this drug, particularly in areas where infections are highly endemic, to identify potential shifts in parasite response and to refine treatment approaches.

Key Studies & References

1. Efficacy of Albendazole and Albendazole-Mebendazole against Trichuris trichiura Infections

Common questions about Немозол (FAQ)

Q: What should I do if I miss a dose of Nemozol?

Official product information advises that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, it is generally advised to skip the missed dose and resume the normal schedule. Taking a double dose to compensate for a missed one is generally not advised.

Q: Is it safe to take Nemozol with food, and does it matter what kind of food?

Nemozol (Albendazole) is generally taken with food to enhance absorption into the body. For some specific conditions, official product information indicates that taking the medicine with a fatty meal can significantly increase the drug’s concentration in the system.

Q: Can children take Nemozol, and if so, what is the right form for them?

Nemozol is available for pediatric use, with dosing adjusted by body weight. For younger children, the oral suspension (liquid form) is typically used. Official information also notes that treatment for children under two years of age is generally not recommended due to limited clinical experience in that age group.

Storage and Disposal Requirements for Nemozol (Albendazole)

Official regulatory documents stipulate specific conditions for the storage of Nemozol to preserve the stability of albendazole. The medicine must be stored at a controlled temperature, typically not exceeding 30 C, and must be protected from both light and moisture. To maintain its integrity, the product should be kept in the original container.

Handling and Safety Rules

For safety, the medication must be universally kept out of the sight and reach of children. Specifically, the oral suspension formulation is subject to the restriction Do not freeze.

Disposal Instructions

To dispose of unused or expired Nemozol, regulatory guidance requires that the product be discarded in accordance with local requirements. This means the medicine should not be thrown into household trash or wastewater unless explicitly permitted by the local pharmaceutical waste program.